Tarsus Pharmaceuticals, Inc. (TARS) Tops Q3 EPS by 33c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q3 EPS of ($0.61), $0.33 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $43.18 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Super League Enterprise (SLE) files for 1.07M share offering by selling stockholders